Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis

Citations Over TimeTop 18% of 2015 papers

Abstract

We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death. We followed 43 children with sickle cell disease from 2000 to 2009 after having a first clinical stroke, of whom 10 opted for HU therapy. HU use led to decreased stroke recurrence and death without significantly increasing the annual cost of care per patient (J$83,250 vs. J$76,901, P = 0.491). The incremental cost effectiveness ratio (ICER) for prevention of stroke recurrence amounted to J$169,238 (US$1,900), while that for death prevention equalled J$635,843 (US$7,140). HU may be recommended when safe and affordable transfusion therapy is not feasible.

Related Papers

• → Therapeutic Milestone(2010)96 cited
• → Stroke Is the Leading Cause of Death in Rural Gadchiroli, India(2015)60 cited
• → Causes of Death in Different Subtypes of Ischemic and Hemorrhagic Stroke(2017)27 cited
• → Defining Cause of Death in Stroke Patients: The Brain Attack Surveillance in Corpus Christi Project(2006)22 cited
• → In-Hospital Mortality in Stroke Patients(2008)9 cited